-56%

est. 2Y upside i

Healthcare

The only R&D data cloud for life sciences

Rank

#1817

Sector

Life Sciences R&D Software

Est. Liquidity

~3Y

Data Quality

Data: Medium

TetraScience presents a strong upside opportunity for a job seeker, driven by its exceptional 111% YoY ARR growth and a robust competitive moat in the burgeoning life sciences R&D software market.

Last updated: March 10, 2026

Bull (45%)+100%

TetraScience solidifies its position as the dominant R&D Data Cloud, expanding its network effects and leveraging AI-native data to capture significant market share from legacy systems. Strategic partnerships, particularly with major players like Thermo Fisher Scientific, accelerate adoption, pushing ARR to over $100M within two years and justifying a $1.6B+ valuation at a premium 16x+ ARR multiple.

Base (40%)+40%

TetraScience continues its strong growth, maintaining its competitive moat against direct competitors like Benchling and fending off incumbent threats. ARR grows to approximately $60M-$70M within two years, leading to an acquisition or IPO at a valuation of around $1.12B, reflecting a healthy 16-18x ARR multiple.

Bear (15%)-40%

Increased competition from well-funded incumbents or a slowdown in life sciences R&D spending limits TetraScience's growth. ARR stalls below $40M, and a challenging market leads to a down round or acquisition at a valuation of $480M. Given $129M in liquidation preferences, common stock value could decline by approximately 48%.

Est. time to liquidity~2.5 years

Preference Stack Risk

high

Investors hold $129M in liquidation preferences, representing 16.1% of the estimated current $800M valuation.

Dilution Risk

moderate

While the latest funding round was small, the company may require additional significant capital raises before a liquidity event, potentially leading to further dilution.

Secondary Liquidity

none

No information was found regarding active secondary markets or tender offers for TetraScience equity.

Questions to Ask at the Interview

Strategic questions based on TetraScience's data — designed to show you've done your homework.

  • 1

    “Given the collaboration with Thermo Fisher Scientific, how does TetraScience plan to navigate the potential incumbent threat from partners who could also become competitors in the data management space?”

  • 2

    “With 111% YoY ARR growth and a stated TAM of $300B, what are the key strategic initiatives to maintain this growth trajectory and expand market penetration beyond the current ~2%?”

  • 3

    “Considering the company's late-stage funding and the $129M in total capital raised, what is the anticipated timeline and preferred path to a liquidity event (e.g., IPO or acquisition) for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.